We firstly investigated on novel combinations of multiple immunomodulatory mAbs, recently isolated in our laboratory, specific for PD-L1, PD-1 or LAG-3, able to strong activate T cells [24–28], with the parental bi-specific tribody (Tb535H) targeting the 5T4-TAA on tumor cells and CD3 on T cells, which already demonstrated anti-tumor efficacy in preclinical studies [23]. This evidence concerns the gene LAG3 and neoplasm.